October 25th 2024
Larimar has undertaken an ongoing open-label extension study of nomlabofusp with the first enrolled patient being dosed in March 2024.
Lexeo Therapeutics' LX2006 Shows Promise in Treating Friedreich's Ataxia Cardiomyopathy
August 9th 2024Given the lack of approved treatments for FA cardiomyopathy, LX2006's potential could represent a breakthrough for patients suffering from a disease characterized by severe cardiac complications.
Read More
Everything You Need to Know About Larimar Therapeutics' Nomlabofusp and the FDA's START Program
August 7th 2024This past May, Larimar Therapeutics, a clinical-stage biotechnology company focused on developing treatments for rare diseases, announced that its lead compound for Friedreich's Ataxia, Nomlabofusp, would participate in the START pilot program. Nomlabofusp is one of the three Center for Drug Evaluation and Research programs and one of the six programs selected by the FDA.
Read More